Hologic (HOLX) Stock Rating Lowered by BidaskClub

BidaskClub lowered shares of Hologic (NASDAQ:HOLX) from a hold rating to a sell rating in a research report released on Friday morning.

A number of other brokerages also recently issued reports on HOLX. Needham & Company LLC reissued a buy rating and set a $50.00 price objective on shares of Hologic in a research report on Thursday, February 1st. Canaccord Genuity downgraded shares of Hologic from a buy rating to a hold rating and cut their price objective for the company from $48.00 to $39.00 in a research report on Thursday, May 3rd. Stifel Nicolaus cut their price objective on shares of Hologic from $42.00 to $40.00 and set a hold rating for the company in a research report on Thursday, May 3rd. Leerink Swann downgraded shares of Hologic from an outperform rating to a market perform rating and cut their price objective for the company from $48.00 to $41.00 in a research report on Thursday, May 3rd. Finally, Zacks Investment Research downgraded shares of Hologic from a hold rating to a sell rating in a research report on Monday, April 30th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and nine have issued a buy rating to the company. Hologic has an average rating of Hold and a consensus price target of $44.87.

Shares of HOLX stock traded up $0.20 during mid-day trading on Friday, reaching $38.92. 1,099,563 shares of the company’s stock traded hands, compared to its average volume of 2,540,172. Hologic has a 12 month low of $35.10 and a 12 month high of $46.80. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.26 and a quick ratio of 0.98. The company has a market cap of $10.57 billion, a price-to-earnings ratio of 18.61, a PEG ratio of 1.82 and a beta of 0.87.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.53. Hologic had a negative net margin of 4.15% and a positive return on equity of 20.86%. The firm had revenue of $789.30 million during the quarter, compared to the consensus estimate of $781.23 million. During the same quarter in the previous year, the firm posted $0.50 EPS. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. equities research analysts expect that Hologic will post 2.23 EPS for the current year.

In other Hologic news, VP Karleen Marie Oberton sold 12,196 shares of the business’s stock in a transaction on Wednesday, May 2nd. The shares were sold at an average price of $40.00, for a total value of $487,840.00. Following the sale, the vice president now owns 13,825 shares in the company, valued at approximately $553,000. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Charles J. Dockendorff purchased 13,000 shares of the firm’s stock in a transaction on Thursday, March 15th. The stock was bought at an average price of $38.80 per share, for a total transaction of $504,400.00. The disclosure for this purchase can be found here. 0.79% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in HOLX. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Hologic in the 1st quarter worth $146,000. Synovus Financial Corp purchased a new stake in Hologic in the 1st quarter worth $164,000. NuWave Investment Management LLC purchased a new stake in Hologic in the 4th quarter worth $199,000. Fiduciary Trust Co. purchased a new stake in Hologic in the 4th quarter worth $208,000. Finally, Advisor Partners LLC purchased a new stake in Hologic in the 4th quarter worth $209,000. Institutional investors and hedge funds own 99.80% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply